Autolus analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL

 

• The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes
• 40% patients are in ongoing remission without subsequent stem cell transplant (SCT) or other intervention
• Ongoing CAR T persistence was associated with improved event-free survival
• Autolus will host a conference call and webcast to discuss the presented data on Saturday June 1, 2024 at 9:30 am EDT/8:30 am CDT/2:30 pm BST (details below)

A conference call and webcast to discuss the presented data will be held at 9:30 am EDT/8:30 am CDT/2:30 pm BST on Saturday June 1, 2024. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.

A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.

https://www.globenewswire.com/news-release/2024/05/31/2891490/0/en/Autolus-Therapeutics-presents-longer-term-follow-up-and-additional-data-analysis-of-Pivotal-Phase-2-FELIX-study-of-obe-cel-for-adult-r-r-B-ALL-in-an-oral-presentation-at-ASCO.html